Sana Biotechnology is a biotechnology company, focusing on utilizing engineered cells as medicines. Co. is developing ex vivo and in vivo cell engineering platforms for treatment across therapeutic areas including oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders, among others. Co.'s ex vivo cell engineering pipeline includes its allogeneic T cell program that target CD19 to treat patients with refractory lymphoma. Co.'s in vivo cell engineering pipeline includes its CAR T cell fusosome product candidates (SG242, SG295) target CD19+ cancer cells, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The SANA YTD return is shown above.
The YTD Return on the SANA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether SANA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SANA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|